Latest article
Fierce Pharma Asia—AstraZeneca-Junshi PD-1 deal; Takeda’s $1.2B diabetes selloff, Ovid epilepsy collab pullout
In a strangely structured deal, AstraZeneca has nationwide licensed Junshi Biosciences' PD-1 inhibitor for only one indication in China. Takeda continued to sell...
Remedy.match: A Bengaluru based mostly start-up seems to create a health ecosystem | Bengaluru
Life is too short to waste time thinking about joining a new gym or picking the right fitness routine. A healthy lifestyle is...
Bodily Inactivity, Non-Communicable Ailments and Nationwide Health Pl
Introduction
Physical inactivity is a major contributing factor in global mortality.1 It is estimated across the world that physical inactivity triggered about 20% of the...